Abstract
Background and Aims: Treatment of hepatitis C virus (HCV) in patients with mental illness has previously been hampered by the adverse neuropsychiatric effects of interferon therapy and difficulties in engaging with the patients using traditional treatment models. In addition, there is little Australian literature describing the prevalence of HCV in psychiatric populations. The new era of direct-acting antiviral (DAA) therapy has renewed interest in the treatment of HCV in this population. The aims of this study were therefore to assess HCV risk factors and prevalence in a large population of acute psychiatric inpatients and to explore treatment models of care.
Original language | English |
---|---|
Pages (from-to) | 67-68 |
Number of pages | 2 |
Journal | Journal of Hepatology |
Volume | 68 |
Issue number | S1 |
DOIs | |
Publication status | Published - Sept 2018 |
Event | Australian Gastroenterology Week 2018: Gut Matters - Brisbane Convention and Exhibition Centre, Brisbane, Australia Duration: 8 Sept 2018 → 10 Sept 2018 |
Keywords
- Hepatitis C
- Psychiatric inpatients
- Mental Illness
- Treatment methods
- Direct acting antiviral drugs